

## GW3965 HCl, LXR agonist

Catalog	Unit
TBI3069-5MG	5 mg
TBI3069-25MG	25 mg

### Product Details

**Formal Name:** 3-[3-[[[2-Chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-benzeneacetic acid, hydrochloride

**Molecular Formula:** C<sub>33</sub>H<sub>31</sub>ClF<sub>3</sub>NO<sub>3</sub> • HCl

**Formula Weight:** 618.5

**CAS Number:** 405911-17-3


**Purity:** >98%

**Formulation:** Powder

**Solubility:** Soluble in DMSO (up to 48 mg/ml)

**Storage:** -20°C

**Stability:** ≥ 2 years.



### Applications

LXR agonist

### Functions

GW3965 is a potent and selective LXR agonist, activating human LXR $\alpha$  and  $\beta$  in cell-based reporter gene assays (EC<sub>50</sub>=190 and 30 nM respectively). Since LXR is a master regulator of cholesterol and fatty acid metabolism, GW3965 exerts a variety of effects including antiatherosclerotic, antiinflammatory as well as antinociceptive and alteration of fat tissue distribution. Orally active.

### Application Procedures

First dissolved in DMSO (48 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 2 months.

**For research use only.**